Krystal Biotech, Inc. (KRYS)
Nasdaq: KRYS · Biological Products, (No Diagnostic Substances) · Pittsburgh, PA · filing with the SEC since 2017
Grade7.6
◀ Past 7.1● Present 9.0▶ Future 6.1
Who owns Krystal Biotech, Inc.
As filed with the SECHolders of 5% or more
3
Blackrock, Inc. holds 11.6% of Common Stock, as its SCHEDULE 13G/A filed Oct 27, 2026 says.
Directors and officers
11
report now, of 17 people on the record since 2017. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Oct 27, 2026 · Common Stock
Krish S. Krishnan
SCHEDULE 13G/A · filed May 4, 2026 · Common Stock, $0.00001 par value ("Common Stock")
Vanguard Portfolio Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
State Street Corporation
SCHEDULE 13G · filed Feb 5, 2025 · COMMON STOCK · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What KRYS reports owning in othersstakes of 5% or more, and other ties
Krystal Biotech, Inc. reports no stake in another company in the record.
Insider tradesForm 4
142sales
0purchases
132sales on a scheduled plan
6people selling
$105Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 18 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Krishnan Krish S | President and CEO | 50 | $34.3M | 50 | 0 | $0 |
| Krishnan Suma | President, R&D | 50 | $34.3M | 50 | 0 | $0 |
| Janney Daniel | director | 22 | $19.4M | 22 | 0 | $0 |
| Rossi Dino A | director | 10 | $13.2M | 0 | 0 | $0 |
| Romano Kathryn | Chief Accounting Officer | 8 | $3.6M | 8 | 0 | $0 |
| Thomas John Charles | EVP, General Counsel | 2 | $500,000 | 2 | 0 | $0 |